Agios Pharmaceuticals (AGIO) has drawn attention after its shares closed at $31.79 on 8 October 2026. This has prompted fresh questions about how the biopharma’s rare disease pipeline aligns with recent trading performance.
Recent trading reflects a mixed picture for Agios Pharmaceuticals, with the 1-day share price return of 0.22% at $31.79 sitting against a 90-day share price decline of 25.71% and a 1-year total shareholder return that is down 25.38%. At the same time, the year-to-date share price return is up 16.96%, suggesting that momentum has cooled after an earlier rebound.
Compare Agios Pharmaceuticals with other rare disease and biotech plays showing similar price dislocations by scanning our curated list of 20 high quality undiscovered gems.
Agios Pharmaceuticals now trades well below both analyst targets and intrinsic value estimates, with that gap widening after the recent slide. The real issue is whether the market or the models are off on this one.
Most Popular Narrative: 28% Undervalued
On the most followed view, Agios Pharmaceuticals screens as undervalued, with a fair value of $44.00 against the recent close at $31.79. The debate shifts to whether the rare disease thesis can support that gap.
Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.
See why 7 investors see Agios Pharmaceuticals as 28% undervalued.
Result: Fair Value of $44 (UNDERVALUED)
Still, the Agios Pharmaceuticals story only holds if PYRUKYND and Aqvesme deliver as expected and if high R&D and SG&A spending do not keep cash burn elevated.
Find out about the key risks to this Agios Pharmaceuticals narrative.
Another View: Multiples Paint a Very Different Picture for Agios Pharmaceuticals
Fair value models point to Agios Pharmaceuticals as deeply undervalued, yet the sales multiple tells a very different story. The stock trades on a P/S of 19.3x, compared with 12.1x for the US Biotechs industry, 5.4x for peers, and a fair ratio of just 0.2x. That gap suggests investors are paying a heavy premium on current revenue, so how comfortable are you with that kind of valuation stretch?
See what the numbers say about this price, find out in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around Agios Pharmaceuticals can pull you in both directions, so check the data now and decide where you stand by weighing 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Agios Pharmaceuticals?
Do not stop with Agios Pharmaceuticals. Broaden your watchlist with a few targeted stock ideas that match your risk appetite, income needs, and balance sheet preferences.
- Target potential mispricing by scanning our curated set of companies that look undervalued on both quality and fundamentals through the 29 high quality undervalued stocks.
- Strengthen your income stream by reviewing businesses that combine higher yields with resilient payouts inside the 8 dividend fortresses.
- Prioritise resilience by filtering for companies with sturdy finances and robust fundamentals using the list of solid balance sheet and fundamentals (25 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com